EPHE, INSERM and Reference Center for Neurogenetic Diseases, MMDN, University Montpellier, CHU, 34095, Montpellier, France.
Service de Génétique, Hôpital Nord, CHU Saint-Etienne, Saint-Etienne, France.
J Neurol. 2024 Sep;271(9):6038-6044. doi: 10.1007/s00415-024-12574-z. Epub 2024 Jul 20.
Ubiquitin C-terminal hydrolase L1 (UCHL1) has been associated with a severe, complex autosomal recessive spastic paraplegia (HSP79) [1] [2] [3] [4]. More recently, UCHL1 loss of function (LoF) variants have been associated to an autosomal dominant disease characterized by late-onset spastic ataxia, neuropathy, and frequent optic atrophy [5].
Routine clinical care whole-genome (WGS) and exome (ES) sequencing.
We present three families with autosomal dominant UCHL1-related disorder. The clinical phenotype mainly associated optic atrophy, mixed cerebellar and sensory ataxia, and possible hearing loss. We delineated two major phenotypes, even within the same family: (1) juvenile severe optic atrophy followed by a later-onset ataxia, or (2) late-onset ataxia with asymptomatic or mild optic atrophy. The families harboured three novel heterozygous variants in UCHL1: two loss of function (p.Lys115AsnfsTer40; c.171_174 + 7del11), and one missense (p.Asp176Asn) involving the catalytic site of the protein and potentially altering the adjacent splice site.
We confirm the existence of dominantly inherited UCHL1 pathogenic variants. We describe a considerable intrafamilial phenotypic variability, with two main phenotypes. Optic atrophy was consistently present, but with varying degrees of severity. Neither delayed motor or intellectual development, nor dysmorphic features were part of the dominant phenotype in comparison with the autosomal recessive form. The molecular mechanism appears to be haploinsufficiency. UCHL1 monoallelic variants should therefore be considered in any case of early-onset optic atrophy or in late-onset complex ataxic syndrome with asymptomatic optic atrophy.
泛素 C 端水解酶 L1(UCHL1)与一种严重的常染色体隐性痉挛性截瘫(HSP79)[1][2][3][4]有关。最近,UCHL1 功能丧失(LoF)变体与一种常染色体显性疾病相关,其特征为迟发性痉挛性共济失调、神经病和频繁的视神经萎缩[5]。
常规临床护理全基因组(WGS)和外显子(ES)测序。
我们介绍了三个常染色体显性 UCHL1 相关疾病的家族。主要的临床表型与视神经萎缩、混合小脑和感觉性共济失调以及可能的听力损失有关。我们描述了两种主要的表型,即使在同一个家族中:(1)青少年严重视神经萎缩,随后出现迟发性共济失调,或(2)迟发性共济失调伴无症状或轻度视神经萎缩。这些家族携带 UCHL1 中的三个新的杂合变体:两个功能丧失(p.Lys115AsnfsTer40;c.171_174 + 7del11)和一个错义(p.Asp176Asn),涉及蛋白的催化位点,并可能改变相邻的剪接位点。
我们证实了显性遗传 UCHL1 致病变体的存在。我们描述了相当大的家族内表型变异性,有两种主要的表型。视神经萎缩始终存在,但严重程度不同。与常染色体隐性形式相比,显性表型中既没有延迟的运动或智力发育,也没有发育不良的特征。分子机制似乎是杂合不足。因此,UCHL1 单等位基因变体应在任何早发性视神经萎缩或迟发性复杂共济失调综合征伴无症状视神经萎缩的情况下考虑。